EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties

Yangqing Deng, Meiling Hao iD, Shao Hui Huang, Geoffrey Liu, John R de Almeida, Wei Xu

Statistics in Medicine · 2025

DOI: 10.1002/sim.70215 ↗

At a glance

Journal article in Statistics in Medicine, 2025. Written by Yangqing Deng and 5 co-authors. Institution: Department of Biostatistics, University Health Network, Toronto, Ontario, Canada. Major MEDLINE topics: Randomized Controlled Trials as Topic. Cited 1 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: Princess Margaret Cancer Foundation, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Overall survival has been used as the primary endpoint for many randomized trials that aim to examine whether a new treatment is non‐inferior to the standard treatment or placebo control. When a new treatment is indeed non‐inferior in terms of survival, it may be important to assess other outcomes including health utility. However, analyzing health utility scores in a secondary analysis may have limited power since the primary objectives of the original study design may not include health utility. To comprehensively consider both survival and health utility, we developed a composite endpoint, HUS (Health Utility‐adjusted Survival), which combines both survival and utility. HUS has been shown to be able to increase statistical power and potentially reduce the required sample size compared to the standard overall survival endpoint. Nevertheless, the asymptotic properties of the test statistics of the HUS endpoint have yet to be fully established. Besides that, the standard version of HUS cannot be applied to or has limited performance in certain scenarios, where extensions are needed. In this manuscript, we propose various methodological extensions of HUS and derive the asymptotic distributions of the test statistics. By comprehensive simulation studies and a data application using retrospective data based on a translational patient cohort in Princess Margaret Cancer Centre, we demonstrate the better efficiency and feasibility of HUS compared to different methods.

Subjects

MeSH terms (MEDLINE)

Randomized Controlled Trials as TopicHumansSurvival AnalysisComputer SimulationModels, StatisticalData Interpretation, StatisticalEndpoint DeterminationRetrospective StudiesSample Size

Author keywords

hazard ratiohealth utilityoverall survivalproportional hazardsrandomized controlled trialstime‐to‐event data

Authors and institutions

  • Department of Biostatistics, University Health Network, Toronto, Ontario, Canada.
  • School of Statistics, University of International Business and Economics, Beijing, China.
  • Department of Radiation Oncology, University Health Network, Toronto, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

ORCID profiles: Meiling Hao

Funding

  • Princess Margaret Cancer Foundation
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Cite

APA

Deng, Y., Hao, M., Huang, S. H., Liu, G., de Almeida, J. R., & Xu, W. (2025). Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties. Statistics in Medicine. https://doi.org/10.1002/sim.70215

Vancouver

Deng Y, Hao M, Huang SH, Liu G, de Almeida JR, Xu W. Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties. Statistics in Medicine. 2025. doi:10.1002/sim.70215

BibTeX
@article{Deng2025,
  author = {Deng, Yangqing and Hao, Meiling and Huang, Shao Hui and Liu, Geoffrey and de Almeida, John R and Xu, Wei},
  title = {Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70215}
}
Start for free →